The Switch Works, the Launches Slip: Initiating Vertex at Hold on a Guide That Turns 8% Revenue Growth Into 3% EPS Growth
Key Takeaways
- A clean operating quarter that beat the company's own frame, not the Street's. Total revenue of $2,986.9M grew 7.8% against the roughly 7% management guided for Q1 on the February call, and non-GAAP EPS of $4.47 beat the $4.23 consensus by 5.7%. The revenue line itself landed within 0.2% of consensus. Nothing in the print required a change to the full-year guide, and none was made.
- The ALYFTREK conversion is doing exactly what it is supposed to do. ALYFTREK reached $424.4M against $53.9M a year ago while TRIKAFTA/KAFTRIO fell 7.1% to $2,354.7M. The two together grew 7.3%, so the switch is additive rather than merely substitutive, and the chief commercial officer's statement that all new patients now start on ALYFTREK means the conversion still has runway.
- Non-CF revenue went backwards sequentially, and that is the problem. CASGEVY plus JOURNAVX totalled $71.9M against $81.0M in Q4 2025. Both landed below Street expectations, CASGEVY by roughly 10% and JOURNAVX by roughly 18%. The full-year target of $500M or more now requires those two products to average about $143M a quarter for three consecutive quarters, close to twice the Q1 level, and management stopped disclosing the CASGEVY infusion count it published every quarter of 2025.
- The guide converts 8% to 9% revenue growth into roughly 3% EPS growth. Combined non-GAAP operating expenses must step up 12.4% to 15.0% from the Q1 run rate to reach the $5.65B to $5.75B range, gross margin is guided to compress from the 87.1% Q1 printed to a full-year figure just under 86%, and the non-GAAP tax rate normalizes from 17.3% in 2025 to 19.5% to 20.5%. Consensus has FY26 EPS at $18.96 against $18.40 delivered in 2025.
- Rating: Initiating at Hold. At the $424.36 reaction close the shares trade at 22.4 times the consensus full-year number for a year in which earnings are roughly flat, and the three events capable of resolving the debate, AMPLIFIED data, VX-828 sweat chloride and the povetacicept launch curve, are all ahead rather than behind. This is a business we want to own; it is not obviously a price at which to start.
Results vs. Consensus
Q1 2026 Scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Total revenue | $2,986.9M | $2,981M | In line | +0.2% |
| EPS, non-GAAP diluted | $4.47 | $4.23 | Beat | +5.7% |
| EPS, GAAP diluted | $4.02 | n/a | n/a | n/a |
| TRIKAFTA/KAFTRIO revenue | $2,354.7M | $2,390M | Miss | -1.5% |
Two notes on the consensus figures above. First, published Q1 revenue estimates ranged from about $2.98B to $3.09B; we use the $2,981M figure because it is the most widely cited and because the alternative at the top of the range sits above the roughly 7% growth management itself framed for the quarter in February, which would imply about $2.96B. Second, no published consensus was available for non-GAAP operating income, non-GAAP gross margin or GAAP EPS, so those rows are left blank rather than back-solved.
CASGEVY at $42.9M and JOURNAVX at $29.0M were both described in the trade press as falling short, by roughly 10% and roughly 18% respectively. We carry those as percentages and deliberately do not translate them into dollar consensus figures, because inverting a rounded percentage to recover a base manufactures precision that was never there.
Year-over-year comparison
| Line ($M unless noted) | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Product revenues, net | 2,986.9 | 2,760.2 | +8.2% |
| Other revenues | 0.0 | 10.0 | n/a |
| Total revenues | 2,986.9 | 2,770.2 | +7.8% |
| Cost of sales, non-GAAP | 384.6 | 355.4 | +8.2% |
| Gross margin, non-GAAP | 87.1% | 87.2% | -0.1pp |
| Research and development, non-GAAP | 859.3 | 879.0 | -2.2% |
| Acquired in-process R&D | 0.5 | 19.8 | -97.5% |
| Selling, general and administrative, non-GAAP | 432.2 | 333.0 | +29.8% |
| Combined operating expenses, non-GAAP | 1,292.0 | 1,231.8 | +4.9% |
| Operating income, non-GAAP | 1,310.3 | 1,183.0 | +10.8% |
| Operating margin, non-GAAP | 43.9% | 42.7% | +1.2pp |
| Interest income, net | 114.8 | 117.9 | -2.6% |
| Effective tax rate, non-GAAP | 19.6% | 18.8% | +0.8pp |
| Net income, non-GAAP | 1,147.0 | 1,054.1 | +8.8% |
| Diluted shares (M) | 256.3 | 259.5 | -1.2% |
| Diluted EPS, non-GAAP | $4.47 | $4.06 | +10.1% |
The GAAP line, and why it flatters
| Line ($M unless noted) | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Operating income, GAAP | 1,138.1 | 630.1 | +80.6% |
| Intangible asset impairment charge | 0.0 | 379.0 | n/a |
| Stock-based compensation | 166.4 | 166.1 | +0.2% |
| Effective tax rate, GAAP | 17.7% | 11.5% | +6.2pp |
| Net income, GAAP | 1,031.4 | 646.3 | +59.6% |
| Diluted EPS, GAAP | $4.02 | $2.49 | +61.4% |
GAAP EPS grew 61.4%, and essentially none of that is operational. The prior-year quarter absorbed a $379.0M intangible asset impairment charge that does not recur, which by itself accounts for most of the $508.0M swing in GAAP operating income. Working the other way, the GAAP tax rate rose 6.2 points because the prior year had both a lower pre-tax base and a larger relative benefit from stock compensation. Anyone marketing this quarter on the GAAP line is marketing an impairment comparison.
Sequential comparison
| Line ($M unless noted) | Q1 2026 | Q4 2025 | QoQ |
|---|---|---|---|
| Total revenues | 2,986.9 | 3,190.0 | -6.4% |
| TRIKAFTA/KAFTRIO | 2,354.7 | 2,572.5 | -8.5% |
| ALYFTREK | 424.4 | 380.1 | +11.7% |
| Other CF products | 135.9 | 156.4 | -13.1% |
| CASGEVY | 42.9 | 54.3 | -21.0% |
| JOURNAVX | 29.0 | 26.7 | +8.6% |
| Gross margin, non-GAAP | 87.1% | 85.7% | +1.4pp |
| Combined operating expenses, non-GAAP | 1,292.0 | 1,362.1 | -5.1% |
| Operating income, non-GAAP | 1,310.3 | 1,370.2 | -4.4% |
| Operating margin, non-GAAP | 43.9% | 43.0% | +0.9pp |
| Effective tax rate, non-GAAP | 19.6% | 13.5% | +6.1pp |
| Diluted EPS, non-GAAP | $4.47 | $5.03 | -11.1% |
The 6.4% sequential revenue decline reads worse than it is. Cystic fibrosis revenue fell 6.2% from Q4 to Q1, against a 5.5% decline over the same two quarters a year earlier, so the first quarter carries its usual US payer-reset and channel drag and this year's version is only modestly heavier. The genuinely new information in this table is one row down: CASGEVY fell 21.0% sequentially in a launch year, and the combined non-CF line fell 11.2% from $81.0M to $71.9M.
- Revenue: in line, and the composition is clean. There is no acquisition, no milestone and no other-revenue line this quarter, versus $10.0M of other revenue in the prior-year quarter. Growth is entirely product volume and price, with an acknowledged foreign-exchange tailwind in the international book. The soft spots are in the two smallest lines, which is where the forward risk sits rather than where the quarter was decided.
- Margins: the 87.1% non-GAAP gross margin is 140 basis points above the 85.7% the company itself named in February as "a reasonable proxy for what to expect in 2026." That is a favourable variance, but it is a mix variance: gross margin is high precisely because the lower-margin non-CF products did not scale. The company reiterated a full-year figure just under 86% anyway.
- Operating expenses: the entire $60.2M increase in combined operating expenses is selling and administrative. Non-GAAP SG&A rose $99.2M while non-GAAP R&D fell $19.7M and acquired IPR&D fell $19.3M. The R&D decline is not a spending decision, and management said so: some povetacicept manufacturing cost moved out of R&D and into cost of sales after the positive interim analysis, and the rest is trial timing.
- EPS: of the 10.1% growth, 8.8 points came from net income and 1.3 points from a 1.2% lower diluted share count. Below the operating line the quarter was a modest headwind, not a help: interest income fell 2.6% and the non-GAAP tax rate rose 80 basis points. This is an operationally earned number.
Revenue assessment. Landing within 0.2% of consensus while beating the company's own February frame of approximately 7% growth is the right way to read this line. The distinction matters because the full-year guide requires the remaining three quarters to deliver 7.9% to 9.6% year-over-year growth, so Q1 at 7.8% is precisely at the bottom edge of what the year needs. Management said in February that growth would accelerate "thereafter and building towards our full year guidance," and Q1 did not accelerate. It also did not need to. The judgement on whether the guide is achievable rests entirely on whether the non-CF ramp arrives, because the CF book on its own is tracking to something like 6% and $12.5B, which lands the company just at the bottom of the range with nothing to spare.
Margin assessment. Gross margin of 87.1% is the single most under-discussed number in the print. It is 140 basis points above the company's stated full-year proxy, and it is high for a reason that is not good news: the product mix shift that is supposed to compress it did not happen this quarter. Operating margin of 43.9% is likewise at the full-year 2025 level, against a guide whose own components imply 41.3% to 42.6% for 2026. Both of those variances are timing, and both reverse if the second half arrives as guided. A company that guides to margin compression and then does not deliver it in Q1 has not beaten its plan; it has deferred it.
EPS assessment. The $0.24 beat is worth about $61M of net income, roughly $77M pre-tax, against a plan, which for a company of this size is close to noise. What is not noise is the shape of the year the guide describes. Non-GAAP EPS of $4.47 is down 11.1% sequentially from a $5.03 fourth quarter that carried a 13.5% tax rate, and the full-year tax guide of 19.5% to 20.5% against 17.3% actual in 2025 costs roughly $0.60 per share on last year's pre-tax base before any operating consideration. Revenue growing 8% to 9% and consensus EPS growing 3.0% is not a rounding difference. It is the whole 2026 story.
Revenue Performance by Product
Vertex reports as a single segment, so the revenue table is the segment disclosure. One presentational change is worth noting: CASGEVY and JOURNAVX were promoted to named lines this quarter, having previously been disclosed only in a footnote to a combined "Other product revenues" caption. Prior periods below are restated onto the new presentation.
| Product ($M) | Q1 2026 | Q1 2025 | YoY | % of total |
|---|---|---|---|---|
| TRIKAFTA/KAFTRIO | 2,354.7 | 2,535.5 | -7.1% | 78.8% |
| ALYFTREK | 424.4 | 53.9 | +687.4% | 14.2% |
| Other CF products | 135.9 | 155.3 | -12.5% | 4.6% |
| Total cystic fibrosis | 2,915.0 | 2,744.7 | +6.2% | 97.6% |
| CASGEVY | 42.9 | 14.2 | +202.1% | 1.4% |
| JOURNAVX | 29.0 | 1.3 | n/m | 1.0% |
| Total non-CF | 71.9 | 15.5 | +363.9% | 2.4% |
| Product revenues, net | 2,986.9 | 2,760.2 | +8.2% | 100.0% |
| Geography | Q1 2026 revenue | YoY | CF-only YoY |
|---|---|---|---|
| United States | $1.78B | +7% | +5% |
| Outside the United States | $1.21B | +9% | +8% |
| Total | $2.99B | +8% | +6% |
The geographic split carries one caveat the company disclosed and one it did not. Disclosed: international growth of 9% includes "a favorable impact from foreign exchange," which management flagged as anticipated. Not disclosed: the size of it. The gap between total US growth of 7% and US CF growth of 5% is the entire contribution of CASGEVY and JOURNAVX, both of which are predominantly American revenue at this stage.
Cystic fibrosis: the conversion is additive
The headline that TRIKAFTA/KAFTRIO fell 7.1% is not the story. TRIKAFTA and ALYFTREK are the same franchise at different points in a deliberate migration, and the correct unit of analysis is the pair. Together they generated $2,779.1M against $2,589.4M a year ago, growth of 7.3%, which is faster than the 6.2% the total CF book delivered. The drag comes from the legacy tail, where KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI fell 12.5% as patients move to the triples. That erosion is intended and finite.
"So at this point, essentially, I would tell you that all new patients are going on to AlifTrack [ALYFTREK], no one is going on to TRIKAFTA, all going on to AlifTrack [ALYFTREK]. We see the discontinued patients largely moving on to AlifTrack [ALYFTREK], and the vast majority, of course, of our patients now are transitions from TRIKAFTA to AlifTrack [ALYFTREK], exactly as we would expect."
— Duncan J. McKechnie, Chief Commercial Officer
Three drivers extend this beyond the switch itself. The FDA approved label extensions for both ALYFTREK and TRIKAFTA covering patients with a clinical CF diagnosis and at least one responsive variant, adding roughly 800 newly eligible US patients. Reimbursement agreements for ALYFTREK were signed in eleven countries in the quarter alone. And submissions for ALYFTREK in ages two to five, and TRIKAFTA in ages one to two, are imminent.
Assessment: the CF franchise is behaving as a well-run monopoly should, and the switch economics are working. What it is not doing is accelerating. Total CF growth of 6.2% against a total-company guide of 8% to 9% means CF alone does not get the company to its number, which places the entire burden of the guide on two products that together are 2.4% of revenue.
CASGEVY: momentum in patients, not in dollars
CASGEVY generated $42.9M, up 202.1% against a near-standing start a year ago and down 21.0% from the fourth quarter. Cumulative patients who have "initiated the treatment journey" passed 500. The company secured a pricing agreement in Germany during the quarter and is working through implementation.
"First-quarter revenue reflects expected variability quarter to quarter as patients choose the timing for their infusion that suits them best. For the full year 2026, the Kasjevi [CASGEVY] outlook is very promising, as we have built our ATC network, secured reimbursements, and now have many patients at all stages of the treatment journey."
— Duncan J. McKechnie, Chief Commercial Officer
The lumpiness explanation is reasonable on its face. A one-time cell therapy recognises revenue at infusion, patient journeys run months, and a quarter is a short window. The difficulty is that this quarter the company also stopped publishing the number that would let anyone verify it. Every quarter of 2025 carried an infusion count, including the disclosure that 30 people were infused in Q4 2025 and 64 across the year, alongside a global first-cell-collection count of 147. This quarter offers only a cumulative "initiated" figure and the word "hundreds" for collections.
Assessment: the installed base of patients moving through the funnel is real and the addressable population, above 60,000 in approved geographies, is large. But a launch that removes its own volume metric in the quarter its revenue declines has made itself harder to underwrite, and the burden of proof now sits with the second quarter.
JOURNAVX: prescriptions up, realisation down
JOURNAVX generated $29.0M on more than 350,000 prescriptions filled, against more than 550,000 filled in all of 2025 for $59.6M. Prescriptions were split roughly evenly between hospital and retail. Cumulative prescriptions written since launch passed one million.
Put those two disclosures together and the picture sharpens. More than 350,000 prescriptions producing $29.0M implies no more than about $83 of net revenue per prescription, against about $108 for full-year 2025 on the same basis. Net realisation per prescription fell roughly a quarter while volume roughly tripled the quarterly pace. That is the patient support programme and the gross-to-net gap doing exactly what management has described, and it is why revenue growth is currently lagging prescription growth rather than leading it.
"Overall, prescription growth remains strong, although Q1 revenue reflects some normal inventory destocking. We remain on track to more than triple the 550 thousand prescriptions from 2025, and for revenue growth to significantly exceed prescription growth."
— Duncan J. McKechnie, Chief Commercial Officer
Access continues to broaden. Roughly 240 million lives are now covered, up from over 200 million in January. Twenty-two states cover the product through Medicaid, up from 21. The field force has doubled to 300 representatives, slightly ahead of plan. And CMS added the product to the NOPAIN Act separate payment list with a retroactive payment date of January 23, 2026.
Assessment: the volume trajectory supports the tripling commitment, though it requires roughly 433,000 prescriptions a quarter for the rest of the year against Q1's 350,000. The revenue trajectory is the open question, and it depends on a gross-to-net normalisation that management has now dated to "by the end of the year" having framed it in February as "late 2026, early 2027." That is a modest pull-forward of a promise, offered in a quarter that missed.
Renal: a fourth franchise with no revenue and rising cost
Povetacicept contributed nothing to the quarter and drove roughly a third of the increase in SG&A. The RAINIER Phase 3 interim analysis in IgA nephropathy hit every endpoint, the rolling BLA was completed in March, and a Priority Review Voucher is being used to compress the FDA review to six months from acceptance. Three further programmes are live: primary membranous nephropathy has moved into the Phase 3 portion of OLYMPUS ahead of schedule, a generalised myasthenia gravis Phase 2 proof-of-concept is underway, and inaxaplin in APOL1-mediated kidney disease has an interim analysis due in early 2027 plus AMPLIFIED data in the second half.
"Our renal field force will be specialty-sized and large enough to cover nephrologists who see approximately 80% of U.S. IgAN patients. We will target key facilities that represent a combination of renal centers, glomerular disease clinics, and key high-volume private practices."
— Duncan J. McKechnie, Chief Commercial Officer
Assessment: this is the reason to own Vertex over a five-year horizon and the reason 2026 earnings do not grow. The commercial infrastructure is being built now against an approval that has not been granted, which is correct sequencing and expensive sequencing. Investors are paying for a launch they cannot yet handicap.
Key Topics & Management Commentary
Overall Management Tone: confident and specific on the pipeline, notably less specific on the commercial ramp. Management volunteered a clinical setback without being asked and answered pipeline questions with numbers, while the two commercial lines that missed were addressed with qualitative explanations and reaffirmed annual targets rather than quantified bridges. Analyst pushback was almost entirely scientific, so the guide's arithmetic went essentially unchallenged on the call.
1. The quarter cleared the company's own bar, and the bar did not move
Management framed Q1 as the opening chapter of a year of delivery rather than as a beat. Total revenue growth of 7.8% came in ahead of the roughly 7% framed on the February call, and the full-year guidance was reiterated line for line with no change to any of the five published metrics.
"Vertex Pharmaceuticals Incorporated is off to a terrific start in 2026, which we see as a year defined by execution."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: reiterating rather than raising after beating your own quarterly frame is a signal, and in this case a reasonable one given where the beat came from. Revenue outperformance driven by CF rather than by the launches does not de-risk a full-year target whose incremental dollars sit with the launches.
2. Diversification is real in the growth rate and small in the base
The company leaned heavily on the statistic that the two newest products drove about a quarter of total growth. The arithmetic is right: CASGEVY and JOURNAVX added $56.4M of the $226.7M year-over-year increase in product revenue, or 24.9%.
"CASGEVY and JOURNAVX delivered more than 25 percent of our growth this quarter, underscoring the strength of the increasingly diversified revenue base."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
The same two products are 2.4% of revenue and declined 11.2% sequentially. Both statements are true. The growth-contribution framing measures the derivative and the mix framing measures the level, and at this stage of a launch only one of them is load-bearing for the full-year guide.
Assessment: the diversification thesis is directionally correct and being marketed one derivative ahead of where it actually is. We would take the sequential decline more seriously than the growth-contribution statistic, because the guide is denominated in dollars.
3. The $500M non-CF target now needs roughly double the Q1 run rate
This is the most consequential number in the print, and it was not discussed on the call in these terms. Non-CF revenue of $71.9M in Q1 leaves $428.1M to be earned across the remaining three quarters to reach the "$500 million or greater" commitment, an average of $142.7M a quarter. That is 1.98 times the first quarter.
"We continue to have high confidence in our outlook for revenue of $500 million or more from non-CF products, driven by growing KASJEVY [CASGEVY] infusions—we have good line of sight given the length of the patient journey—and a meaningful ramp in GERNAVICS [JOURNAVX] prescriptions and revenue as gross-to-net normalizes through the second half of the year."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
The visibility claim is not unreasonable for CASGEVY specifically. A cell therapy with a months-long patient journey genuinely does give a company sight of its own revenue two quarters out, which is why the company can assert line of sight while declining to quantify it. But "line of sight" and "we told you the number" are different disclosures, and only one of them is checkable.
Assessment: a doubling is achievable off a base this small, and the year-over-year comparison is helpful: the remaining three quarters need $428.1M against $159.9M a year earlier. It is nonetheless the single largest source of variance in the full-year revenue guide, and Q1 moved in the wrong direction. We model non-CF revenue at roughly $430M, below the commitment.
4. Gross margin came in 140 basis points above the company's own full-year proxy
In February the CFO explicitly nominated the fourth-quarter figure as the planning assumption for the year. Q1 printed 87.1% against that 85.7% proxy, and the full-year guide was reiterated unchanged.
"Our outlook for full-year gross margin remains at just under 86%, reflecting the growing non-CF product mix impact and ongoing investments in manufacturing network and process development for various products."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
Read against the mix explanation, the Q1 outperformance and the non-CF shortfall are the same fact seen twice. Gross margin held up because the dilutive products did not scale. Holding the full-year guide unchanged therefore embeds a view that the mix effect still arrives, which requires the non-CF ramp the same guide depends on for revenue.
Assessment: we carry full-year gross margin at 86.0%, above the company's proxy, precisely because we carry non-CF revenue below the company's target. Those two adjustments are the same adjustment, and a reader who believes the $500M target should also believe the 85.7% margin.
5. Operating expenses must step up 12% to 15% from here
Combined non-GAAP operating expenses of $1,292.0M were 5% above the prior year and 5.1% below the fourth quarter. Against the $5.65B to $5.75B full-year range, the remaining three quarters must average $1,452.7M to $1,486.0M, a step-up of 12.4% to 15.0% from the Q1 level.
"First-quarter 2026 combined non-GAAP R&D, acquired IPR&D, and SG&A expenses were $1.29 billion, an increase of 5% compared to $1.23 billion in 2025."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
The composition of the increase is entirely commercial. Non-GAAP SG&A rose $99.2M year over year while non-GAAP R&D fell $19.7M and acquired IPR&D fell $19.3M, netting to the $60.2M increase in the combined line.
"Non-GAAP SG&A expenses increased 30% year over year, driven primarily by commercial investments—roughly 40% attributable to GERNAVICS [JOURNAVX] in pain and approximately one third to renal launch programs."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
Applying those proportions to the $99.2M increase puts roughly $40M behind a pain franchise that generated $29.0M of revenue in the quarter and roughly $33M behind a renal franchise that generated none. That is the correct investment for a company with two credible launches in front of it, and it is also the mechanism by which 8% revenue growth becomes 3% earnings growth.
Assessment: the ramp is a plan rather than a commitment, and plans of this kind routinely underspend when the approval they are built against slips. We model $5.68B, modestly below the midpoint, which is one of the two places we sit above consensus on margin.
6. The R&D decline is a reclassification, not a spending cut
Non-GAAP R&D fell 2.2% year over year in a quarter in which the company is running four mid-to-late-stage renal programmes, two Phase 3 pain studies, three next-generation CFTR correctors and a restarted type 1 diabetes trial. Management gave the reason without prompting.
"Within total OpEx, non-GAAP R&D expenses were down 2% year over year, partly driven by the timing and mix of certain clinical trial expenses. In addition, certain Povi [povetacicept] manufacturing expenses were included in R&D in 2025 and are now recorded in cost of sales following the positive interim analysis data."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
Assessment: a reported R&D decline that is partly a transfer into cost of sales and partly trial timing should not be extrapolated. It also means the reported 87.1% gross margin absorbed povetacicept manufacturing cost that the prior-year comparative did not, which makes the margin outperformance marginally better than it looks and the R&D line correspondingly worse.
7. Povetacicept: the data were unambiguous and the filing was fast
The RAINIER Phase 3 interim analysis delivered a 52% reduction from baseline in 24-hour UPCR, a 49.8% reduction against placebo, a 77.4% reduction in serum GdIgA1, hematuria resolution in 85.1% of affected patients, and 42.2% of patients reaching UPCR below 0.5 g/g, all at 36 weeks of treatment. Serious adverse events of infection ran at 0.5% in both the treated and placebo arms.
"Overall, the Phase III interim analysis data represent a home run in terms of study design, execution, and results, with Povi [povetacicept] achieving statistically significant and clinically meaningful results across all primary and secondary endpoints."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
"Indeed, at 27 days from database lock to regulatory submission, this was the fastest submission in Vertex history."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: on the evidence available this is a strong dataset and an impressive execution result, and it is the principal reason we would not rate the stock below Hold. The commercial question it does not answer is what proteinuria superiority is worth against a competitor that already holds accelerated approval and is about to present longer-duration kidney-function data.
8. VX-522 was discontinued, and the last 5,000 CF patients go back to the drawing board
The mRNA programme intended for people who produce no CFTR protein, and therefore cannot benefit from any modulator, was terminated. The early termination precludes any assessment of efficacy or full safety.
"Despite actions we have taken in the trial to overcome these issues, we have not been able to do so, and as such, we have chosen to discontinue the program."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: disclosed cleanly and without hedging, which is to the company's credit. The financial impact is immaterial and the strategic impact is not: the roughly 5,000 patients this programme addressed remain unreachable, the delivery problem is unsolved, and management characterised the path forward as returning to modality selection rather than iterating on the current one.
9. Zimislecel is dosing again, without a timeline
The type 1 diabetes cell therapy resumed dosing after the manufacturing analysis that paused the study in the second half of 2025 was completed. Multiple patients have been dosed. The clinical results to date remain striking: among patients who received a full dose with at least a year of follow-up, ten of twelve were insulin free.
"With dosing now restarted, we will update you in the coming months on the revised timelines, study completion, and regulatory filings."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: resumption removes the worst-case interpretation of the pause, and the deferral of timelines to "the coming months" is the second consecutive quarter in which this programme's schedule has been an open item. We carry no value for it.
10. Capital returns funded the share count flat, not down
The company deployed $344M to repurchase more than 741,000 shares, an average of roughly $464 per share at the stated share count, against a $424.36 close on the reaction day.
"We ended the quarter with $13 billion in cash and investments after deploying approximately $344 million to repurchase more than 741 thousand shares in the first quarter."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
Shares outstanding nonetheless rose from 254.0M at year end to 254.2M at March 31, and weighted-average diluted shares rose from 256.1M to 256.3M sequentially. First-quarter vesting makes a single quarter noisy, and on a year-over-year basis the buyback is working: basic shares fell 1.1% and that contributed 1.3 points of the 10.1% EPS growth. But roughly a point of the Street's 3.0% full-year EPS growth is buyback, which leaves the operating business contributing about two.
Assessment: $13.0B of cash and marketable securities against a business that generates roughly $1.1B of non-GAAP net income a quarter is an enviable position and an underused one. Repurchasing 0.3% of the company at a price above the current one is not a capital-allocation error, but it is not a thesis either.
11. Tariffs remain a stated non-event with no number attached
Both the release and the call address tariffs, and neither quantifies anything.
"On the subject of tariffs, we do not expect any material impact to the income statement in 2026. We continue to evaluate the details of recent announcements and the potential applicability to Vertex Pharmaceuticals Incorporated."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
Assessment: the 2026 assurance is credible given inventory positioning and the guidance language, which describes an "immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations." The conditional in that sentence is doing real work, and nothing was said about 2027 for a company with substantial ex-US manufacturing and roughly 40% of revenue outside the United States.
Guidance & Outlook
| Metric | Prior FY 2026 guide | New FY 2026 guide | Change |
|---|---|---|---|
| Total revenue | $12.95B to $13.10B | $12.95B to $13.10B | Maintained |
| Non-CF product revenue | $0.5B or greater | $0.5B or greater | Maintained |
| Combined GAAP R&D, AIPR&D and SG&A | $6.30B to $6.45B | $6.30B to $6.45B | Maintained |
| Combined non-GAAP R&D, AIPR&D and SG&A | $5.65B to $5.75B | $5.65B to $5.75B | Maintained |
| Non-GAAP effective tax rate | 19.5% to 20.5% | 19.5% to 20.5% | Maintained |
| Full-year gross margin (call only) | Just under 86% | Just under 86% | Maintained |
Every line was reiterated. The revenue range represents growth of 8% to 9% off the $12,001.3M delivered in 2025, and the difference between the GAAP and non-GAAP expense ranges is principally $650M to $700M of stock compensation. Both expense ranges include roughly $100M of anticipated acquired IPR&D, so a business-development transaction of any size would push the GAAP line beyond its stated range.
"We are reiterating our 2026 total revenue guidance of $12.95 billion to $13.10 billion, representing growth of 8% to 9%. This outlook reflects continued solid performance from the CF franchise driven by the AlifTrack [ALYFTREK] launch, expansion into younger patient groups, incremental patients from the label expansion, and geographic expansion."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer
Implied quarterly ramp. Q1 revenue of $2,986.9M leaves $9,963.1M to $10,113.1M for the remaining three quarters, an average of $3,321.0M to $3,371.0M. That is 11.2% to 12.9% above the first quarter in absolute terms, and 7.9% to 9.6% above the corresponding $9,231.1M earned in the last three quarters of 2025. Consensus places the second quarter at $3.18B, which would leave the third and fourth quarters needing $3,391.6M to $3,466.6M each, or 6.3% to 8.7% above the $3,190.0M record set in the fourth quarter of 2025.
Implied operating-margin path. Take the guide at its own components. Applying the 85.7% gross margin the company nominated, the revenue range and the expense range produce full-year non-GAAP operating income of $5,348M to $5,577M against $5,263M in 2025, growth of 1.6% to 6.0% on revenue growth of 8% to 9%. Full-year operating margin lands at 41.3% to 42.6% against 43.9% last year. Q1 delivered 43.9%, so all of the guided compression sits in the remaining nine months, where the implied operating margin is 40.5% to 42.2%.
Street at. Consensus sits at $13.01B of revenue and $18.96 of non-GAAP EPS for the full year, essentially at the revenue midpoint and 3.0% above the $18.40 delivered in 2025. That EPS figure requires either full-year gross margin above the company's own 85.7% proxy or operating expenses at the bottom of the range. Working backwards, $18.96 implies roughly $5,605M of operating income, about $143M above what the guide's stated components produce at their midpoints. Consensus is, in effect, assuming the Q1 margin variance persists. We assume some of it does, which is why our number is close to but below the Street's.
Guidance style. The pattern is conservative in the near term and unchanged in the aggregate. Management framed Q1 at approximately 7% and delivered 7.8%. Revenue estimates have been topped in each of the last four quarters and EPS in three of four. Set against that record, reiterating rather than raising the full year after a first-quarter beat is the company signalling that the beat was in the wrong place to change the annual picture.
Analyst Q&A Highlights
Whether the renal franchise can genuinely rival cystic fibrosis
The opening question went straight to the largest claim the company makes about itself, asking what has to happen for renal to reach CF scale and which asset carries the most value. The answer was built on epidemiology rather than on commercial modelling: four programmes across four diseases, each individually rare but collectively addressing hundreds of thousands of patients in the West, in a therapeutic area where untreated progression leads to dialysis or transplant. On the second half of the question management declined to rank the assets in any durable way, naming povetacicept while explicitly conceding the choice was coloured by the recency of its data.
Q: "So you have talked about renal one day rivaling the cystic fibrosis business in size. Can you speak to what needs to play out from here to realize that vision? And among your renal assets, which you see having the greatest long-term revenue potential?"
— Jessica Fye, JPMorgan
A: "The reason I think that this has the potential to be as big if not larger than CF is that the diseases that these medicines treat are rare diseases, but they are common rare diseases. And when you add them all up together, they are well into the hundreds of thousands of patients."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: the patient-count argument is sound and the pricing argument was left entirely implicit. CF revenue rests on near-universal genotype coverage, decades of reimbursement precedent and orphan pricing sustained across two decades. Reaching that scale in nephrology requires all three to be rebuilt in markets with far more payer scrutiny. The ambition is credible on a ten-year view and should not be discounted into a 2026 multiple.
Convincing prescribers to switch from an approved first mover
A question on commercial differentiation drew the most concrete competitive answer of the call. Management structured its case around three claims: dual BAFF and APRIL inhibition rather than APRIL alone, monthly rather than weekly dosing, and small-volume subcutaneous auto-injector administration, each supported by market research on physician and patient preference. Notably, the response engaged the mechanism debate directly while never naming the competitor.
Q: "With the Povi launch not too far off, what do you think you will need to convey to KOLs and community physicians to convince them of povitacicept differentiation and overcome first mover advantage by competitors?"
— Brian Abrahams, RBC Capital Markets
A: "We also know from our market research that those nephrologists that distinguish between BAFF/APRIL and APRIL alone, the vast majority of them preferred dual inhibition with BAFF and APRIL. And in our patient market research, the vast majority of patients prefer monthly dosing over weekly dosing. In fact, eight times more patients prefer monthly dosing to weekly dosing."
— Duncan J. McKechnie, Chief Commercial Officer
Assessment: stated preference in market research is the weakest form of commercial evidence, and the caveat embedded in the answer is revealing: the preference for dual inhibition holds among nephrologists "that distinguish between" the two mechanisms, which is a self-selecting subset. The dosing-frequency advantage is the more durable argument because it is a fact about the label rather than an opinion about biology.
The eGFR endpoint that cannot be shown
The most substantive scientific exchange concerned the endpoint on which full approval actually turns. Management drew a sharp distinction between the hard clinical endpoint of death, dialysis or transplantation, the regulatory-enabling endpoint of two-year eGFR, and proteinuria as the near-term proxy, then disclosed a constraint that materially shapes how the competitive comparison can be made ahead of a competitor's own data presentation.
Q: "On Povi, do you believe that on the efficacy standpoint your differentiation on eGFR will be able to come through over 9 or 12 or 24 months versus, say, Otsuka, which I think is presenting their eGFR 9-month data next month and then their 2-year data coming up?"
— Michael Yee, UBS
A: "The agency has said very clearly that we are not allowed to share eGFR, but they have equally said that they need to see eGFR to provide accelerated approval. So what I would say is any medicine in IgAN that gets accelerated approval has the proteinuria that we have already shared and has an eGFR that the agency finds comforting."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: this is the most important exchange on the call. Management has seen the eGFR data, cannot show it, and is asking the market to infer its adequacy from the fact of a regulatory submission. That is a reasonable inference and it is not the same as evidence. It also means the head-to-head comparison against the approved incumbent will be made on the incumbent's disclosed kidney-function data against our proteinuria data, which is not a comparison that can be won on the merits until approval.
Reconciling $29M of pain revenue against 350,000 prescriptions
The only question of the call that pressed on the commercial ramp asked management to reconcile the revenue line with the volume line, and whether further formulary work was needed for gross-to-net to normalise. The response attributed the quarter to three factors, channel destocking, Medicare Part D plan resets driving abandonment, and a weak elective-surgery January compounded by flu season, then upgraded a piece of guidance mid-answer by disclosing that coverage had been secured at a second of four Part D plans since the script was written.
Q: "Could you maybe help reconcile the $29 million in revenue in the first quarter with the volume of either prescriptions or pills? And then, given that GERNAVICS has PBM coverage for 240 million lives now, which is over two thirds of the population, does GERNAVICS need to achieve more employer opt-ins and more Tier 2 formulary positions for the gross-to-net to normalize?"
— David Risinger, Leerink Partners
A: "In terms of reconciling Q1 and volume, as I mentioned in the prepared remarks, we did see a small but relatively normal channel inventory destocking in Q1 between Q4 2025 and Q1 2026. ... As we have said all along, as we secure the final pillars of access, the patient support program will taper down, our gross-to-net will normalize by the end of the year, and you will see revenue significantly accelerate and accelerate faster than prescription growth as we go through the balance of the year."
— Duncan J. McKechnie, Chief Commercial Officer
Assessment: the question asked for a reconciliation and received a list of explanations, which is not the same thing. None of the three factors was sized, and the answer moved from the quarter that happened to the year that is promised without quantifying the bridge between them. The Part D disclosure was genuinely new and genuinely positive. The failure to put a number on gross-to-net, in the one exchange that invited it, is the disclosure gap of the call.
What the mRNA discontinuation means for untreatable patients
Questioning on the terminated CF programme sought both the mechanism of the tolerability failure and the strategic response. Management identified the failure as lung inflammation, most likely a response to the lipid nanoparticle delivery vehicle rather than to the payload, and framed the path forward as a delivery problem rather than a therapeutic-modality problem.
Q: "I want to expand a little bit on the discontinuation of VX-522. Anything else you can share on the tolerability issues? And then, looking ahead, do you plan to utilize another technology to help these patients that are not currently treatable with your current portfolio?"
— Evan Seigerman, BMO Capital Markets
A: "On VX-522, what I can tell you is that the tolerability issue that we have been monitoring and sharing with you, now that the study is being discontinued, has to do with lung inflammation—an inflammatory response, probably in response to the LNP that is being used to deliver it."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: attributing the failure to the delivery vehicle rather than the therapeutic hypothesis preserves the strategic option, and the reasoning is plausible given the known inflammatory profile of inhaled lipid nanoparticles. It also resets the timeline for this patient population to something measured in years. The candour is worth noting: the discontinuation was volunteered in prepared remarks before any question forced it.
The bar for advancing the broader kidney-disease population
A follow-on question sought the threshold at which the second APOL1 study, covering patients with moderate proteinuria or comorbid diabetes, would justify carrying that population forward. Management gave an unusually explicit numerical bar, which is rare on a call of this kind and useful for handicapping a readout due in the second half.
Q: "When you think about the pending data from AMPLIFIED looking at AMKD patients with moderate proteinuria or diabetes, what is needed in this population for a clinically meaningful benefit to justify advancement in this patient segment?"
— Cory Kasimov, Evercore ISI
A: "I would say that, generally speaking, in renal, we have been thinking about double-digit improvements as being valuable. By that, I do not mean 10% or 11%. I would say if we can show a 30% improvement—some number between 20% and 40%, 25% and 50%—some solid double-digit improvement in proteinuria on top of standard of care, of course—so, on top of ACEs, ARBs, SGLT2s, etc.—that would be meaningful."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: pre-committing to a numerical bar before a readout is a credibility-positive act, because it makes the result gradeable rather than spinnable. Note the context, though: the registrational study in the primary population delivered 47.6% proteinuria reduction in Phase 2, so a 20% to 40% bar in this adjacent population is being set well below the precedent the company itself established. That is appropriate for a harder population and it is also a lowered expectation stated in advance.
Whether anything is left to improve in cystic fibrosis
The final exchange produced the most strategically important admission of the call, and it came in response to a question about where headroom remains in a franchise the company has dominated for two decades. Management described a therapeutic area approaching saturation on its own primary measure, with two thirds of patients already at normal sweat chloride on a once-daily medicine.
Q: "And then, just as you think about the cystic fibrosis landscape overall, how are you thinking about the bar set by AlifTrack versus where you see room for incremental improvement?"
— Unidentified analyst, Barclays
A: "Now, fast forward to where we are today with AlifTrack [ALYFTREK], and, genuinely, there is very little unmet need. And so it is going to take something special for us to advance, and that is why we are looking at VX-828, VX-581, and VX-2272 [VX-272], because we want to really interrogate to see if there is more that we can bring to the table."
— Reshma Kewalramani, M.D., Chief Executive Officer and President
Assessment: this is the clearest statement any Vertex management team has made that the CF franchise is approaching its clinical ceiling. It is a scientific triumph and a commercial constraint in the same sentence. Once the ALYFTREK conversion completes, CF growth reverts to patient additions, geographic expansion and price, which is a mid-single-digit business. Everything above that rate has to come from somewhere else, which is precisely why the non-CF shortfall matters more than its 2.4% revenue weighting suggests.
What They're NOT Saying
- The CASGEVY infusion count disappeared. Every quarter of 2025 carried one, including 30 patients infused in the fourth quarter and 64 across the year, together with 147 first cell collections globally. This quarter, in which CASGEVY revenue fell 21.0% sequentially, discloses only cumulative patients who have "initiated the treatment journey" and the word "hundreds" for collections. A launch metric that is retired in the quarter it would have looked worst is the clearest signal in the release.
- No second-quarter revenue frame was offered. On the February call management explicitly guided Q1 to approximately 7% growth. This call offered no equivalent number for Q2, only that growth builds toward the full-year figure. Removing a disclosure the company voluntarily provided one quarter earlier, in a year where the shape of the ramp is the central question, narrows what anyone can check before August.
- The $500M non-CF target was never split. Management has now reaffirmed the aggregate three times without indicating how much belongs to CASGEVY and how much to JOURNAVX. Given that one is a lumpy one-time cell therapy with claimed line of sight and the other is a prescription product with an acknowledged gross-to-net problem, the split is the whole information content of the target.
- Gross-to-net on the pain franchise remains unquantified. Directly asked to reconcile $29.0M of revenue against more than 350,000 prescriptions, management supplied three qualitative factors and no arithmetic. Our own calculation puts net realisation at no more than about $83 per prescription against roughly $108 for full-year 2025. If that figure is wrong the company is in a position to correct it and has chosen not to.
- No cash flow statement, and no cash flow discussion. The release contains an income statement, a revenue table, a non-GAAP reconciliation and a balance sheet. Operating cash flow, capital expenditure and free cash flow appear nowhere, and were not raised on the call. This is the company's long-standing practice rather than a change, but it means the $676M sequential increase in cash and securities is the only visible cash datum, alongside inventories that rose $79.9M and receivables that fell $56.7M.
- Zimislecel timelines were deferred again. Dosing has resumed, which is the news, and the revised schedule for study completion and regulatory filings is once more promised for "the coming months." That is now two consecutive quarters in which this programme's timeline has been an open item.
- Nothing was said about 2027 tariffs. The 2026 assurance is explicit and conditioned on "currently known tariff rates and regulations." For a company with roughly 40% of revenue outside the United States and substantial ex-US manufacturing, the absence of any framing beyond the current year is a real gap rather than a rhetorical one.
- The competitor was never named. Asked directly about a rival APOL1 dataset, management prefaced its answer by declining to comment on other companies' assets and then compared the top-line numbers anyway. On IgA nephropathy, where a competitor already holds accelerated approval, the incumbent went unmentioned in prepared remarks entirely.
Market Reaction
- Pre-print setup: VRTX closed at $429.85 on Monday May 4, down 5.2% year to date against an S&P 500 up 5.2%, down 14.2% over the trailing twelve months and down 2.0% over the trailing thirty days. The 52-week closing range entering the print was $366.54 to $501.15, placing the stock roughly 14% below its 52-week closing high and about 17% above the low. This is a de-rated setup, not a crowded one.
- After-hours move: the release crossed after the close with the call at 4:30 p.m. ET. The shares were little changed on the print itself and drifted to roughly 1% lower through the after-hours session.
- Next-day session: the stock opened at $431.99 on Tuesday May 5, a 0.5% gap up, traded down to $412.27 intraday, or 4.1% below the prior close, and closed at $424.36, down 1.3% or $5.49.
- Volume: 1.9M shares against a 1.2M thirty-day average, or 1.6 times normal.
- Index context: the S&P 500 rose 0.8% on the same session, leaving roughly 2.1 points of relative underperformance.
The intraday path is more informative than the close. A stock that gaps up half a point, sells off four points, and then recovers two thirds of that drawdown by the bell is describing a disagreement that resolved into a shrug. The gap up is the headline print: revenue in line, an EPS beat, a full-year guide untouched. The drawdown is what happens when the product table is read: both launch products below expectations, non-CF revenue down sequentially, and the fourth-quarter CASGEVY infusion count nowhere to be found. The recovery is the pipeline reasserting itself, because a povetacicept BLA already filed with a priority voucher is worth more to this equity than a $9.1M sequential shortfall across the two launch products.
What the 1.6 times volume rules out is a repositioning. A move of this size on this participation is existing holders trimming at the margin, not a change in who owns the stock. That is consistent with the setup: entering the print down 14.2% over twelve months against an index that was up, the shares were not carrying expectations that a quarter like this could disappoint.
The move also prices almost nothing about the second half. At $424.36 the stock trades at 22.4 times the consensus full-year number for a year in which that number grows 3.0%. A market genuinely underwriting a nephrology franchise "that can rival, if not crest, CF" would not settle there, and a market genuinely worried that the $500M non-CF target is unreachable would have taken more than 1.3%. The reaction is best read as the market declining to re-rate in either direction until AMPLIFIED, VX-828 and the povetacicept approval resolve it.
Street Perspective
Debate: Is the ALYFTREK switch creating growth or relocating it?
Bull view: The bull case on the Street is that the eightfold jump to $424.4M signals a healthy switch rate and that the pair of TRIKAFTA plus ALYFTREK grew 7.3% year over year, faster than the CF book as a whole. On this reading the conversion is not cannibalisation at all: it is a product upgrade that improves persistence, extends patent life and brings newly labelled patients into a franchise with a fresh runway of paediatric approvals.
Bear view: The bear camp contends that a 7.3% growth rate on the combined pair, in a quarter flattered by an acknowledged currency tailwind and a one-time 800-patient label expansion, is what peak looks like. Management's own description of "very little unmet need" in CF is the concession. Strip out the switch and the underlying business is patient adds plus price, which is mid-single digits at best and decelerating as the legacy tail, down 12.5%, runs out of patients to lose.
Our take: The bulls have the near term and the bears have the terminal value, and the disagreement is about when rather than whether. The switch is genuinely additive today, and the paediatric approvals plus geographic expansion give it two to three more years of visible support. But management said on this call that the clinical ceiling is close, and that is a statement about the growth rate on the other side of the conversion. A CF business compounding at 5% to 6% is a superb asset and it is not a growth story, which places the entire growth premium in this multiple on assets that have not launched.
Debate: Can non-CF revenue reach $500M this year?
Bull view: Some on the Street argue the first quarter is structurally the wrong quarter to extrapolate. Cell-therapy revenue recognises at infusion and patient scheduling is genuinely lumpy; the pain product faced Part D resets, a weak elective-surgery January and channel destocking simultaneously; and the access work that governs realisation, a second Part D plan secured, roughly 240 million lives covered, a doubled field force, NOPAIN Act inclusion, all landed at or after quarter end. The company has line of sight into a months-long cell-therapy funnel that the market cannot see.
Bear view: The bear framing is arithmetic. Non-CF revenue fell 11.2% sequentially and needs to average $142.7M a quarter for three quarters to reach $500M, close to twice the Q1 level, in a year when the company reaffirmed the target without splitting it and simultaneously withdrew the infusion metric that would have made the cell-therapy half verifiable. Both products missed the Street. Neither missed by a rounding error.
Our take: The bears have the better of this. The year-over-year comparison is achievable, since the remaining three quarters need $428.1M against $159.9M a year earlier, and launches do inflect. But the specific combination of a sequential decline, a withdrawn volume disclosure, an unquantified gross-to-net bridge and a refusal to split the target is a lot of opacity to accept on a line that carries the whole revenue guide's incremental risk. We model roughly $430M, and note that missing $500M by $70M costs only about half a point of total revenue growth, which is why the market can afford to be relaxed about it and we cannot.
Debate: What is povetacicept worth against an incumbent that is already approved?
Bull view: A growing consensus view is that the RAINIER interim is a best-in-class dataset and that the market is not paying for it. A 49.8% placebo-adjusted proteinuria reduction at 36 weeks with serious infection rates identical to placebo, delivered monthly by auto-injector into a US population of roughly 160,000 patients of whom the great majority sit far from guideline targets, is a multi-billion-dollar opportunity that the company can reach with a specialty field force covering nephrologists treating 80% of patients.
Bear view: The bear camp points out that a competitor received accelerated approval in November 2025, is presenting longer-duration kidney-function data imminently, and will have been in the market for roughly a year before povetacicept can launch. Vertex cannot show its own eGFR data by regulatory instruction, so the differentiation case must be argued on proteinuria and dosing convenience against a rival that will hold the endpoint regulators actually require for full approval. First-mover advantage in a chronic biologic, where switching an established patient is harder than starting a new one, is not a small thing.
Our take: Both sides are arguing about a launch curve neither can see, which is itself the answer for a twelve-month rating. The dataset is strong and the dosing profile is a genuine, label-level advantage rather than a claimed one. But an eGFR comparison that cannot be made until approval is a real handicap in exactly the physician conversations that decide share, and the earliest meaningful commercial evidence is more than a year away. We carry no povetacicept revenue in 2026 and no explicit value for it in the base case, which is the honest position when the differentiating evidence is embargoed.
Model Framework at Initiation
We are initiating coverage without a prior model, so the table below sets out our working assumptions rather than changes to an existing one.
| Item | Our assumption | Company guide | Rationale |
|---|---|---|---|
| FY26 total revenue | $12.96B | $12.95B to $13.10B | Just above the bottom of the range. CF at roughly $12.53B on 6.2% growth, consistent with Q1's rate and normal seasonality, plus non-CF below the company's target. |
| FY26 non-CF product revenue | ~$430M | $0.5B or greater | Below the commitment. Reaching $500M requires $142.7M a quarter against $71.9M in Q1, and Q1 fell 11.2% sequentially. |
| FY26 gross margin (non-GAAP) | 86.0% | Just under 86% | Slightly above guide, and for the same reason non-CF is below it. Q1 printed 87.1% because the dilutive mix did not arrive; a smaller non-CF ramp means a smaller mix drag. |
| FY26 combined operating expenses (non-GAAP) | $5.68B | $5.65B to $5.75B | Modestly below the midpoint. The implied 12.4% to 15.0% step-up from Q1's $1,292.0M is a plan built partly against an approval not yet granted. |
| FY26 interest income, net | $450M | Not guided | Q1's $114.8M annualised, easing slightly as cash funds buybacks and the renal build. |
| FY26 effective tax rate (non-GAAP) | 20.0% | 19.5% to 20.5% | At the midpoint. Q1 printed 19.6% and the 2025 rate of 17.3% carried one-time credit benefits that do not repeat. |
| FY26 diluted shares | 255.5M | Not guided | Q1 at 256.3M, declining about a point over the year if the buyback pace holds. |
| FY26 non-GAAP diluted EPS | $18.52 | Not guided | Growth of 0.7% against $18.40 in 2025, and 2.3% below the $18.96 consensus. The gap is our lower non-CF revenue, only partly offset by our higher gross margin. |
| Povetacicept revenue in the base case | Nil in 2026 | n/a | No approval yet granted. We carry no launch revenue and no explicit pipeline value until the label and the launch curve exist. |
| Zimislecel, VX-828, inaxaplin | Nil | n/a | All three have readouts or timeline updates due in the second half of 2026 or early 2027. None is handicappable today. |
Valuation: at the $424.36 reaction close, with 254.2M shares outstanding, market capitalisation is $107.9B. Deducting $13.0B of cash and total marketable securities gives an enterprise value of $94.9B. That is 22.9 times our $18.52 full-year estimate, 22.4 times the $18.96 consensus, and 7.3 times enterprise value to our revenue estimate. There is no dividend.
Fair value: applying 21 to 25 times to our $18.52 gives a range of $389 to $463 with a midpoint of $426. Against the $424.36 close that is roughly 0.4% of expected price appreciation and, with no dividend, essentially the same figure as an expected twelve-month total return. The multiple band is deliberately wide, because a business with 97.6% of revenue in a franchise approaching its clinical ceiling and a genuinely credible second act deserves neither a growth multiple nor a terminal one until the second act starts generating revenue. Povetacicept approval and a visible launch curve would move us to the top of that band and beyond it; a second consecutive quarter of non-CF revenue going sideways would move us to the bottom.
Thesis Scorecard Post-Earnings
This is first coverage, so the pillars below are established here rather than graded against a prior quarter. Each carries the status it holds after this print, and each becomes the standing scorecard against which subsequent quarters are graded.
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: The CF franchise is a durable monopoly with a live conversion cycle | Confirmed | ALYFTREK at $424.4M against $53.9M, TRIKAFTA plus ALYFTREK up 7.3% together, all new patients starting on ALYFTREK, label expansion adding roughly 800 US patients, paediatric submissions imminent. The conversion is additive and has runway. |
| Bull #2: Renal is a credible fourth franchise, led by povetacicept | Confirmed | RAINIER interim hit every primary and secondary endpoint at 36 weeks with placebo-matched serious infection rates. BLA completed in 27 days from database lock, using a Priority Review Voucher. Three further renal programmes advancing, one ahead of schedule. |
| Bull #3: The balance sheet funds the build without external capital | Confirmed | $13.0B of cash and total marketable securities, up $676M sequentially, while funding $344M of buybacks and a four-programme renal build. No financing risk attaches to any of the pipeline decisions. |
| Bear #1: Non-CF diversification is running behind its own plan | Confirmed | CASGEVY and JOURNAVX both below Street expectations, combined revenue down 11.2% sequentially to $71.9M against a target requiring roughly $142.7M a quarter. The CASGEVY infusion count was withdrawn in the same quarter. |
| Bear #2: Earnings growth is decoupling from revenue growth | Confirmed | The guide converts 8% to 9% revenue growth into 3.0% consensus EPS growth through a 12.4% to 15.0% operating expense step-up, guided gross margin compression and a tax rate normalising from 17.3% to 19.5% to 20.5%. |
| Bear #3: Povetacicept launches into an approved incumbent | Neutral | The competitor has held accelerated approval since November 2025 and presents longer-duration kidney-function data imminently. Vertex cannot show its own eGFR data by regulatory instruction, so differentiation must be argued on proteinuria and dosing until approval. |
Overall: the thesis established here is that Vertex owns an exceptional franchise entering a transition year, in which the CF engine is approaching its clinical ceiling, the successor engines are real but not yet earning, and the reported income statement absorbs the cost of the second while the first stops accelerating. Nothing in this quarter contradicts that. The pipeline pillars are stronger than we expected and the commercial pillars are weaker.
Action: hold. The quality of this business does not need re-arguing and the price does not reward starting a position today. We would add on evidence that non-CF revenue has inflected, on the AMPLIFIED and VX-828 readouts due in the second half, or on a povetacicept approval with a visible launch curve, and we would reassess downward on a second consecutive quarter of non-CF revenue tracking sideways against an unchanged $500M target.